Cipla Limited — Fosfomycin Exporter Profile
Indian Pharmaceutical Exporter · #1 for Fosfomycin · $6.0M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Fosfomycin with $6.0M in export value and 120 verified shipments. Cipla Limited holds a 46.6% market share in Fosfomycin exports across 2 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Fosfomycin Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Fosfomycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $5.8M | 118 | 99.9% |
| SPAIN | $3.6K | 2 | 0.1% |
Cipla Limited exports Fosfomycin to 2 countries. The largest destination is UNITED STATES accounting for 99.9% of Cipla Limited's Fosfomycin shipments. These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fosfomycin from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $4.8M | 96 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $1.1M | 22 |
| KIND ATTN; MR. JAUME ROQUET | SPAIN | $3.6K | 2 |
Cipla Limited supplies Fosfomycin to 3 buyers globally. The largest buyer is CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES), followed by CIPLA USA INC UPS SUPPLY CHAIN SOL (UNITED STATES) and KIND ATTN; MR. JAUME ROQUET (SPAIN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fosfomycin Export Value and How Much Does Cipla Limited Contribute?
India exported $8.2M worth of Fosfomycin through 492 shipments from 73 suppliers to 46 countries, serving 88 buyers globally. Cipla Limited contributes $6.0M to this total, accounting for 46.6% of India's Fosfomycin exports. Cipla Limited ships Fosfomycin to 2 countries through 3 buyers.
What Is the Average Shipment Value for Cipla Limited's Fosfomycin Exports?
Cipla Limited's average Fosfomycin shipment value is $50.0K per consignment, based on 120 shipments totaling $6.0M. The largest destination is UNITED STATES (99.9% of Cipla Limited's Fosfomycin exports).
How Does Cipla Limited Compare to Other Indian Fosfomycin Exporters?
Cipla Limited ranks #1 among 73 Indian Fosfomycin exporters with a 46.6% market share. The top 3 exporters are CIPLA LIMITED ($6.0M), SWISS PARENTERALS LIMITED ($1.4M), SRS PHARMACEUTICALS PRIVATE LIMITED ($285.3K). Cipla Limited processed 120 shipments to 2 destination countries.
What Fosfomycin Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORA | $1.6M | 32 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ; ANDA : 211881 ;NDC : 69097-579-67 | $1.1M | 21 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ANDA 211881 NDC 69097-579-67 | $750.0K | 15 |
| FOSFOMYCIN TROMETHAMINE GRANULES FORORAL SOLUTION ; ANDA : 211881 ;NDC : 69097-579-67 (1 X 8 GM) | $500.0K | 10 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ; ANDA : 211881 ;NDC :69097- 579-67 (1X8 GM) | $327.9K | 7 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ANDA 211881 NDC 69097-579-67 1 X 8 GM | $250.0K | 5 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ANDA 211881 NDC 69097-579-67NOS | $200.0K | 4 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ; ANDA : 211881 ;NDC : 69097-579-67 (1 X 8 GM) | $200.0K | 4 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ANDA 211881 NDC 69097 579 67 PAC SIZE 1X8GMX7008 PAC 7008 NOS | $100.0K | 2 |
| FOSFOMYCIN TROMETHAMINE GRANULES FOR ORAL SOLUTION ; ANDA : 211881 ; NDC : 69097579-67 PACK SIZE : 1 X 8 GM | $100.0K | 2 |
Cipla Limited exports 26 distinct Fosfomycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FOSFOMYCIN TROMETHAMINE GRANULES FOR ORA with 32 shipments worth $1.6M.
Regulatory Requirements: Exporting Fosfomycin to Key Markets
What Cipla Limited must comply with to export Fosfomycin to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Fosfomycin Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $6.0M | 120 | 2 | $50.0K |
| 2 | SWISS PARENTERALS LIMITED | $1.4M | 27 | 2 | $50.0K |
| 3 | SRS PHARMACEUTICALS PRIVATE LIMITED | $285.3K | 9 | 2 | $31.7K |
Cipla Limited ranks #1 among 73 Indian Fosfomycin exporters. Average shipment value of $50.0K compared to the market average of $112.6K. The closest competitors by value are SWISS PARENTERALS LIMITED and SRS PHARMACEUTICALS PRIVATE LIMITED.
Which Indian Ports Ship Fosfomycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 99 | 20.1% |
| DELHI AIR CARGO ACC (INDEL4) | 86 | 17.5% |
| SAHAR AIR | 77 | 15.7% |
| DELHI AIR | 50 | 10.2% |
| Bombay Air | 24 | 4.9% |
| JNPT/ NHAVA SHEVA SEA | 24 | 4.9% |
| AHEMDABAD AIR ACC (INAMD4) | 16 | 3.3% |
| NHAVA SHEVA SEA (INNSA1) | 16 | 3.3% |
Geopolitical & Trade Policy Impact on Cipla Limited's Fosfomycin Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Fosfomycin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fosfomycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fosfomycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 120 individual customs records matching Cipla Limited exporting Fosfomycin, covering 26 formulations to 2 countries via 3 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 46+ countries, 88+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fosfomycin Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Fosfomycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Fosfomycin Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fosfomycin. For current shipment-level data, contact TransData Nexus.